Document Detail


Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis.
MedLine Citation:
PMID:  18612769     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Acute myeloid leukemia (t-AML) is one of the worst adverse events of mitoxantrone treatment, but the exact risk in multiple sclerosis (MS) patients is not yet known. We describe a case wherein the patient developed t-AML 11 months after mitoxantrone had been discontinued. The patient was treated by polychemotherapy and autologous bone marrow transplantation with complete recovery of t-AML and stabilization of the neurological disease.
Authors:
Marco Capobianco; Simona Malucchi; Stefano Ulisciani; Carmen Fava; Giovanna Rege Cambrin; Luigina Avonto; Giuseppe Saglio; Antonio Bertolotto
Related Documents :
2719579 - Ophthalmic manifestations of leukemia.
8366299 - Usefulness of terminal deoxynucleotidyl transferase as prognosticator in leukemia patie...
18061959 - A correlation study of immunophenotypic, cytogenetic, and clinical features of 180 aml ...
12609839 - Telomerase and telomere length in multiple myeloma: correlations with disease heterogen...
20072149 - Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressi...
8375859 - Multifocal necrotizing leukoencephalopathy with pontine predilection in immunosuppresse...
2348239 - Periarticular tumoral calcinosis and hypercalcemia in a hemodialysis patient without hy...
22992339 - Interstitial pneumonia associated with mpo-anca: clinicopathological features of nine p...
2719579 - Ophthalmic manifestations of leukemia.
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2008-07-09
Journal Detail:
Title:  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology     Volume:  29     ISSN:  1590-1874     ISO Abbreviation:  Neurol. Sci.     Publication Date:  2008 Jun 
Date Detail:
Created Date:  2008-07-09     Completed Date:  2008-10-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100959175     Medline TA:  Neurol Sci     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  185-7     Citation Subset:  IM    
Affiliation:
Centro di Riferimento Regionale Sclerosi Multipla & Neurobiologia Clinica, Aou S Luigi Gonzaga, Regione Gonzole 10, Orbassano TO, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bone Marrow Transplantation
DNA Topoisomerases, Type II / antagonists & inhibitors,  metabolism
Dose-Response Relationship, Drug
Enzyme Inhibitors / adverse effects
Female
Humans
Immunosuppressive Agents / adverse effects*
Leukemia, Myeloid, Acute / chemically induced*,  physiopathology
Mitoxantrone / adverse effects*
Multiple Sclerosis / drug therapy*
Remission Induction
Treatment Outcome
Chemical
Reg. No./Substance:
0/Enzyme Inhibitors; 0/Immunosuppressive Agents; 65271-80-9/Mitoxantrone; EC 5.99.1.3/DNA Topoisomerases, Type II

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Acute Akinesia, an unusual complication in Parkinson's Disease: a case report.
Next Document:  The first Italian family with evidence of pyramidal impairment as phenotypic manifestation of Silver...